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Abstract
Background: Thus far, live attenuated SIV has been the most successful method for vaccinating macaques against
pathogenic SIV challenge; however, it is not clear what mechanisms are responsible for this protection. Adoptive transfer
studies in mice have been integral to understanding live attenuated vaccine protection in models like Friend virus. Previous
adoptive transfers in primates have failed as transferred cells are typically cleared within hours after transfer.
Methodology/ Principal Findings: Here we describe adoptive transfer studies in Mauritian origin cynomolgus macaques
(MCM), a non-human primate model with limited MHC diversity. Cells transferred between unrelated MHC-matched
macaques persist for at least fourteen days but are rejected within 36 hours in MHC-mismatched macaques. Cells trafficked
from the blood to peripheral lymphoid tissues within 12 hours of transfer.
Conclusions/Significance: MHC-matched MCM provide the first viable primate model for adoptive transfer studies. Because
macaques infected with SIV are the best model for HIV/AIDS pathogenesis, we can now directly study the correlates of
protective immune responses to AIDS viruses. For example, plasma viral loads following pathogenic SIV challenge are
reduced by several orders of magnitude in macaques previously immunized with attenuated SIV. Adoptive transfer of
lymphocyte subpopulations from vaccinated donors into SIV-naı ¨ve animals may define the immune mechanisms
responsible for protection and guide future vaccine development.
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Introduction
2.5 million individuals were infected with human immunode-
ficiency virus (HIV) in 2007. While antiretrovirals and improved
education are critical to curbing the pandemic, the enormous
number of new infections emphasizes the need for a prophylactic
vaccine. However, two recent vaccine failures underscore that we
do not yet have a firm understanding of the immunologic
mechanisms responsible for control of viral replication [1–4].
These disappointing results intimate an urgent need for exper-
iments that more accurately identify those immune responses that
contribute to protective immunity and should be elicited by future
vaccines.
Protective immune responses are evident in humans and
macaques that spontaneously control HIV and simian immuno-
deficiency virus (SIV) replication, respectively. 0.3% of individuals
have undectectable HIV plasma viremia in the absence of
treatment [5], as do a comparable number of SIV-infected
macaques [6–8]. Intensive genetic, immunologic, and virologic
characterization of these individuals have failed to unambiguously
identify the exact immune responses (or combinations of
responses) that need to be elicited in a successful vaccine [9].
Cellular immune responses are clearly important, as evidenced by
the 100–10,000-fold increase in plasma viral load following
transient elimination of CD8+ T lymphocytes from SIV-
controlling macaques [10].
These results provide hope that certain immune responses
capable of controlling HIV and SIV exist, though eliciting these
responses by prophylactic vaccination has proven enormously
frustrating. Of all the vaccines tested to date, only attenuated
‘vaccine’ strains of SIV reliably and consistently elicit immune
responses that control replication of pathogenic virus. However,
this vaccine strategy is not safe for use in humans. Attenuated SIV
is overtly pathogenic in neonatal macaques and sporadically
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of these vaccines to research studies of protective immunity.
Therefore, the fundamental goal of ongoing studies of attenuated
SIV is to define the immunological mechanisms responsible for
protection, with the long-term aim of priming similar immune
responses using safer vaccine modalities. However, extensive
research to date has been unable to identify protective immune
responses in macaques vaccinated with attenuated SIV.
The only retrovirus for which protective immune responses have
been identified is friend virus (FV) [13]. FV is similar to SIV in that
immunization withattenuatedvirusesprotects frompathogenicvirus
challenge [14,15]. Adoptive transfer experiments in mice delineated
the need for a multifactorial vaccine-elicited immune response to
protect against wildtype FV challenge. Neither CD8+ T cells nor
CD4+ T cells alone prevented persistent infection after transfer to
naive mice [16]. Instead, B cells, CD4+ T cells, and CD8+ Tc e l l s
acted in concert to provide protection from persistent infection.
Comparable adoptive transfer studies are needed to identify the
minimal immune responses elicited by attenuated vaccines that
control pathogenic SIV replication. Unfortunately, the genetic
heterogeneity of the macaque major histocompatibility complex
(MHC) has precluded using non-human primates in allogeneic
adoptive transfer studies [17].
Previous adoptive transfer experiments in HIV and SIV studies
have relied on autologous transfers or transfers between identical
twins. These experiments have primarily focused on reconstituting
the immune system in HIV+ persons or on testing the therapeutic
effects of transferring SIV-specific cytotoxic T cells expanded in
vitro [18–24]. Studies have also demonstrated the ability for
peptide pulsed autologous cells to induce enhanced SIV and HIV
specific T cell immunity in addition to recirculation of the labeled
cells [25]. Additional studies have attempted selectively expanding
different subsets of memory T cells, using different methods to
expand cells, or transducing cells to express HIV-1 specific TCR
chains [26–28]. These experiments using cultured cells have met
with limited success due to the rapid clearance or death of
transferred cells [19,29–32]. However, none of these studies have
been capable of investigating the mechanisms responsible for
controlling viral loads in the context of live, attenuated
vaccination. Several investigators have cited the lack of an
adoptive transfer system in macaques to study protective immunity
as a major obstacle to the development of an effective HIV vaccine
[33,34].
We recently identified a geographically isolated population of
cynomolgus macaques from the Indian Ocean island of Mauritius
(MCM) that have extremely limited MHC diversity [35]. We
hypothesized that allogeneic lymphocytes would persist when
transferred between feral, or wild caught, 2-MHC-haplotype-
matched unrelated MCM, as these animals are MHC class I and
II identical. Since only seven haplotypes account for all MHC
diversity in MCM, pairs of MHC-identical animals can be easily
defined using a panel of polymorphic microsatellite markers [35].
For example, an MCM that has haplotypes H1/H2 is 2-MHC-
haplotype-matched (completely MHC matched) to an H1/H2
MCM, 1-MHC-haplotype-matched to an H1/H3 MCM and 0-
MHC-haplotype-matched (mismatched) to an H3/H4 MCM.
MCM offer the unprecedented opportunity to explore protective
immunity elicited by attenuated vaccines through adoptive
transfer of lymphocytes from vaccinated macaques into naive
MHC-matched macaques followed by pathogenic challenge. Here
we demonstrate that allogeneic lymphocytes persist for at least 14
days in 2-MHC-haploypte matched recipients and demonstrate
that lymphocytes traffic to lymphoid tissues after transfer,
confirming the unique suitability of MCM for adoptive transfer
studies and establishing a framework for deciphering the correlates
of SIV-specific protective immunity.
Results
Microsatellite genotyping identifies MHC-identical, MLR-
nonresponsive MCM
Eight MHC-defined MCM were used in this study. The animals
were subdivided into two groups of three animals (MCM1-MCM3
and MCM5-MCM7) that are 2-MHC-haplotype-matched. MCM4
and MCM8 were included as 0-MHC-haplotype-matched controls
(Fig. 1A). The predicted MHC class I and class II alleles encoded on
each haplotype were defined in previous studies [35,39].
Initially, the histocompatibility of 2-MHC-haplotype-matched
MCM was assessed in vitro using a modified mixed lymphocyte
reaction (MLR). Peripheral blood mononuclear cells (PBMC) from
MCM6 were labelled with PKH67, a fluorescent cell membrane
dye that segregates evenly during cell division [40,41]. A reduction
in PKH67 intensity indicates cellular proliferation. PKH67-
labelled PBMC from MCM6 were cocultured with irradiated
autologous, 2-MHC-haplotype-matched (MCM7), 0-MHC-hap-
lotype-matched (MCM8), and 0-MHC-haplotype-matched rhesus
macaque PBMC. PKH67 staining of CD8+ and CD4+ lympho-
cytes from MCM6 were analyzed after six days. Both CD8+
lymphocytes (Fig. 1B) and CD4+ lymphocytes (data not shown)
from MCM6 proliferated when incubated with irradiated PBMC
from either an Indian rhesus macaque or the 0-MHC-haplotype-
matched MCM8. In contrast, the proliferation observed when
labelled PBMC from MCM6 were incubated with irradiated
PBMC from 2-MHC-haplotype-matched MCM7 was similar to
the proliferation observed with irradiated autologous cells (Fig. 1B).
We observed similar results in other pairs of 2-haplotype-matched
MCM (data not shown). This encouraging in vitro data suggested
lymphocytes would be tolerated when transferred between 2-
MHC-haplotype-matched allogeneic MCM in vivo.
Autologous CD8b+ lymphocyte transfer in MCM
We chose to focus our initial studies on the transfer of CD8b+ T
cells. CD8b is frequently used as a marker for CD8 T cells that are
both CD3+ and CD8+ [42]. CD8b+ T cells are archetypical of the
refined lymphocyte subpopulations that could be examined in
allogeneic transfer experiments. Previous experiments depleting
CD8+ cells with monoclonal antibody have not distinguished
between effects on the CD8+ T cell and CD8+ natural killer cell
compartments, so understanding the role of CD8b+ T cells alone
in SIV control could significantly advance our understanding of
protective immunity [43]. Additionally, since CD8b+ T cells
comprise approximately 10–20% of total lymphocytes in the
blood, successful transfer of these cells would strongly suggest that
other surface marker-defined lymphocyte subpopulations at
comparable frequencies, such as CD4+ cells, B cells, and NK
cells, or immunodominant CD8+ epitope-specific T cells, could be
transferred alone or in combination from a donor animal and
subsequently tracked in the recipient [44,45].
We initially performed an autologous transfer to assess CD8b+
T cell purification, fluorescent labeling, in vivo persistence of
labeled CD8b+ T cells, and trafficking of labeled donor cells in
blood (Fig. 2A). We magnetically purified CD8b+ T cells from
MCM6 PBMC by staining with anti-CD8b-PE antibodies. We
enriched for our stained cells using anti-PE microbeads and
magnetic columns. We passed the cells over the columns twice and
obtained greater than 99% purity for CD8b+ cells in the
lymphocyte gate (Fig. 2B). We elected to label the purified
CD8b+ T cells with PKH67 due to this dye’s high fluorescent
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over other commercially available labels such as CFSE. We
reinfused the labelled cells into MCM6 approximately 8 hours
after the initial blood draw through the saphenous vein, and we
monitored the persistence of PKH67+ cells in MCM6 by flow
cytometry. Five minutes post-transfer we drew blood from the
femoral vein and the transfused cells accounted for approximately
2.0% of CD8b+ T cells in the blood (Fig. 2B). After twenty-four
hours, this number declined to 0.38%. The percentage of
PKH67+ CD8b+ T cells remained constant for the next 14 days
(Fig. 2C). PKH67+ CD8b+ T cells were detectable at low levels in
PBMC for 49 days post-transfer, demonstrating the stability of the
labelled lymphocytes in vivo. We also harvested an inguinal lymph
node three days post-transfer and found that PKH67+ cells
accounted for 0.02% of CD8b+ cells in the lymph node (Fig. 2D).
The presence of cells in the lymph node provided evidence of
trafficking despite the in vitro manipulations.
Allogeneic CD8+ lymphocyte transfer between 2-MHC-
haplotyped-matched unrelated MCM
Building on the successful autologous transfer, we performed a
CD8b+ T cell transfer between unrelated, 2-MHC-haplotype-
matched MCM1 and MCM2 (Fig. 3A). We purified and PKH67
labelled CD8b+ T cells from MCM1 as described above and
transferred them into MCM2. Five minutes after infusion into
MCM2, the PKH67+ labelled cells accounted for nearly 1% of
total CD8b+ T cells in the blood (Fig. 3B). Twenty-four hours post
transfer, the PKH67+ labelled cells had decreased to nearly 0.6%
Figure 1. In vitro histocompatibility of MHC-matched MCM. A Microsatellite analysis was used to identify 2-MHC-haplotype-matched, 1-MHC-
haplotype-matched, and 0-MHC-haplotype-matched MCM. MHC haplotypes inferred by microsatellite typing [35] are colored to show matching
between individuals. Predicted MHC class I and class II alleles for each haplotype are shown. We identified 8 MCM for use in these experiments. B
Results from mixed lymphocyte reactions. Whole PBMC from MCM6 was labelled with fluorescent dye PKH67 and incubated with irradiated
stimulator cells as indicated above each plot. Cells that divide after recognizing non-self antigen lose fluorescence as indicated by a decrease along
the y-axis. Dot plots are gated on lymphocytes according to forward and side scatter.
doi:10.1371/journal.pone.0002384.g001
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cells persisted for at least 14 days post-transfer in MCM2. We also
detected cells in the inguinal lymph node 10 days post transfer
(Fig. 3C). To our knowledge, this is the first description of a
successful allogeneic lymphocyte transfer between two unrelated,
non-human primates without immunosuppressive therapy.
2-MHC-Haplotype Matched MCM Tolerate Adoptive
Transfer of More than 2610
8 Lymphocytes
Next we sought to investigate how many lymphocytes could be
safely transferred and whether persistence of transferred lympho-
cytes is MHC-dependent. We transferred CD8b+ T cells from an
SIV+ donor into recipient animals that were 0-MHC-haplotype-
matched, 1-MHC-haplotype-matched, and 2-MHC-haplotype-
matched (Fig. 4A). We were particularly interested in determining
whether an MHC homozygous animal would be an appropriate
donor for a 1-MHC-haplotype-matched recipient as this could
dramatically expand the number of recipient animals available for
future transfer experiments.
Three weeks following intrarectal (IR) challenge with SIV-
mac239, we isolated over 6.5 billion cells from PBMC, spleen, and
lymph nodes of MCM1 for transfer into animals MCM3, MCM4,
and MCM5. We successfully isolated, labelled, and transferred
220 million CD8b+ cells into each of the three recipients.
Transferred cells accounted for 4.7% to 14.7% of the CD8b+ cells
in the PBMC of the recipient animals five minutes post-transfer
(Fig. 4B) without any detectable adverse effects.
After36hoursthedonorcellsweredetectableonlyinthe2-MHC-
haplotype-matched recipient, MCM3. The rapid elimination of
PKH67+ CD8b+ T cells in the 0-MHC-haplotype-matched
recipient (MCM4) and 1-MHC-haplotype-matched recipient
(MCM5) underscores the unique suitability of 2-MHC-haplotype-
matched MCM for allogeneic lymphocyte transfers. Hybrid
resistance and missing-self killing by natural killer cells may explain
the rejection of cells in the 1-MHC-haplotype-matched recipient
[36–38]. The matched recipient had detectable viral RNA in plasma
after the transfer suggesting the animal was infected by cell-
associated virus (data not shown). This result demonstrates the
importance of using vaccinated animals in future transfers.
The donor cells persisted for at least nine days in PBMC and
lymph node of the 2-MHC-haplotype-matched animal MCM3
(Fig. 4C). PKH67+ cells accounted for a greater percentage of
Figure 2. Autologous adoptive transfer. A Diagram displaying the transfer protocol. B Selection for CD8ß+ cells. The left panel is unmanipulated
PBMC. The right panel is the positive fraction collected following CD8ß enrichment gated on lymphocytes. C Transfused cell persistence after
transfer. Percentages are of total CD8ß+ cells in the PBMC of the animal based on the lymphocyte gate. D PKH67+ cells in lymph node of animal
MCM6. The right inguinal lymph node was processed three days post-transfer to measure persistence of PKH67+ cells. The percentage of PKH67+
cells is based on total CD8ß+ cells in the lymph node lymphocyte gate.
doi:10.1371/journal.pone.0002384.g002
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believe the differences observed in the detection of cells in the
PBMC between the first allogeneic transfer and this larger transfer
can be explained by differences in the donor transfusate
composition (Fig. 3 and Fig. 4). The PBMC only accounted for
approximately 2% of the transfusate in the transfer to MCM3,
MCM4, and MCM5; thus, it is likely that we transferred no more
than 4 million CD8b+ cells from PBMC into each of the three
recipient animals. Our data suggests that cells harvested from
spleen and lymph node preferentially trafficked from the blood
into peripheral lymphoid tissues after transfusion.
In this transfer experiment we also verified that persisting
PKH67+ CD8b+ T cells originated from donor MCM1. We took
advantage of differences at microsatellite markers in non-MHC
loci between donor MCM1 and 2-MHC-haplotype-matched,
recipient MCM3. At 7 days post-transfer, we sorted PKH67+ cells
from MCM3 PBMC, isolated genomic DNA, and performed
microsatellite analysis. PKH67+ cells possessed the same micro-
satellite profile as the donor animal, MCM1 (Fig. 5A). These
results confirm that the persisting PKH67+ CD8b+ T cells
originated from the donor animal.
Figure 3. Allogeneic transfer from MCM1 to MCM2. A Diagram displaying the transfer protocol. B PKH67+ donor cells from MCM1 in PBMC of
recipient 2-MHC-haplotype-matched MCM2. Dot plots are gated on lymphocytes and display CD8ß+ lymphocytes only. C Right Axillary lymph node
sample 10 days post-transfer.
doi:10.1371/journal.pone.0002384.g003
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Diagram displaying the transfer protocol. B Donor CD8ß+ cells were transferred from MCM1 into 2-MHC-haplotype-matched MCM3, 0-MHC-
haplotype-matched MCM4, and 1-MHC-haplotype-matched MCM5 and monitored for persistence in recipient PBMC. 220 million CD8ß+ were
transferred to each animal. Donor cells were a composite of CD8ß+ cells enriched from PBMC, mesenteric lymph node and spleen. C Left inguinal
lymph node sample 9 days post-transfer.
doi:10.1371/journal.pone.0002384.g004
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haplotype matched unrelated MCM
We peformed another allogeneic transfer experiment between
2-haplotype-matched MCM to determine if cells were trafficking
to additional tissues besides peripheral lymph nodes (Fig. 6A).
Furthermore we used bulk PBMC in this experiment to monitor
the trafficking pattern of different lymphocyte subsets. We
transferred 60 million bulk PBMC from MCM7 into MCM6.
Twenty-four hours post-transfer we euthanized MCM6 and
examined tissue biopsies for the presence of PKH67+ cells. We
found that CD3+ cells, but not CD3- cells, trafficked to lymph
nodes (Fig. 6B). These CD3+ cells contained roughly equal
proportions of CD4+ and CD8+ T cells (data not shown).
Histology of the lymph nodes also showed the presence of
PKH67+ cells (Fig. 6C). Both CD3+ and CD3- cells were detected
in blood, spleen, and liver, including CD19+ B cells. PKH67+ cells
were below the limit of detection in the mucosal tissues we
sampled including, lung, duodenum, jejunum, and colon. While
cells were not detected in the mucosal tissues, we only processed a
small sample from each of these tissues. Donor cells were not
harvested from the mucosal tissues which may have increased the
presence of transferred cells in recipient mucosal tissues.
Discussion
In these studies we describe a novel adoptive transfer model in
macaques that can directly assess the contributions of cellular and
humoral immune responses to protective immunity in macaques.
In addition to being the first description of allogeneic adoptive
transfers in nonhuman primates without immunosuppression, the
successful transfer of bulk PBMC as well as specific lymphocyte
subpopulations suggests that this system could be immediately
applied to answer questions about the correlates of protective
immune responses.
Differences at minor histocompatibility antigens may have limited
the long-term in vivo persistence of transferred cells beyond two
weeks.Nonetheless, ourresultsclearlyshow thattransfersbetween2-
MHC-haplotype-matched MCM are successful in a way that cannot
be replicated in 1-MHC-haplotype-matched MCM or in other
primate populations such as rhesus macaques where haplotype
sharing between outbred animals is extremely rare [46].
In future experiments, it may be desirable to perform adoptive
transfers without the need for fluorescent dye labeling. The
development of non-fluorescent, genetic detection methods will
help identify transferred cells when the dye is no longer detectable.
Even though 2-MHC-haplotype-matched animals have identical
genetics in the MHC loci, polymorphisms at other genetic loci can
be used successfully to differentiate donor and recipient lympho-
cytes. For example, our laboratory has developed a panel of PCR-
SSP assays for killer-immunoglobulin receptor (kir) genes that
differentiate MCM that are MHC-identical. The use of genetic
markers should eliminate problems with inconsistent labeling and
completely circumvent cell viability or functionality issues
introduced by dye labeling, even though in vitro cyotkine detection
assays suggest that the PKH67 labeling does not obviously affect
cellular function (data not shown).
Provocative research questions that have previously been the
exclusive purview of inbred animal models that are distantly
removed from humans can now be addressed in the macaque
model. The histocompatibility of allogeneic lymphocytes also
suggests that 2-MHC-haplotype-matched MCM could be used for
preclinical testing of differentiated stem cell therapies. Addition-
ally, with macaques being used extensively as models for a
plethora of human health studies besides AIDS, including SARS,
tuberculosis, biodefense, transplant and cancer research; 2-MHC-
haplotype-matched MCM offer enormous opportunities to rapidly
advance our understanding of protective immunity.
Yet perhaps the most immediate application of this model is in
AIDS research. The lack of a nonhuman primate allogeneic
lymphocyte transfer model has been repeatedly cited as a major
obstacle to HIV vaccine development [33,34]. Adoptive transfers
present a straightforward approach to defining the correlates of
protective immunity. Attenuated SIV vaccine strains have been
effective at protecting against wild type SIV challenge. However,
the precise mechanisms driving this protection remain unclear.
Lymphoctyes from animals vaccinated with attenuated SIV could
be transferred to naive recipients shortly before wild-type SIV
challenge. In the last two years, two prerequisites for these types of
studies have been fulfilled. First, We showed that MCM are
susceptible to infection with the highly pathogenic SIVmac239
strain that is often used as a challenge following attenuated
vaccination [35]. Second, MCM immunized with live, attenuated
SIVmac239Dnef before exposure to SIVmac239 exhibit a 3–4
log10 blunting of peak acute SIV viremia (data not shown). This
difference in acute phase peak viral load provides a measurable
indicator of protection in future adoptive transfer experiments,
essentially establishing a 3–4 log10 reduction in viral load as the
benchmark for success, irrespective of whether the transferred cells
are bulk lymphocytes, individual lymphocyte subsets, combina-
tions of lymphocyte subsets, or in vitro manipulated lymphocytes.
Since peak SIV viremia occurs approximately 14 days post-
infection, coincident with the persistence of adoptively transferred
lymphocytes, it is reasonable to speculate that adoptively
transferred cells may influence peak viremia. Furthermore, if
lymphocytes with protective attributes can be transferred between
animals, it will be possible to compare the protection afforded by
Figure 5. Allogeneic transfer cell analysis. A PKH67+ PBMC from
recipient MCM3 were sorted from total PBMC by flow cytometry. We
performed microsatellite analysis to demonstrate that the mircosatellite
profile of PKH67+ cells in the recipient animal matched the
microsatellite profile of donor MCM1.
doi:10.1371/journal.pone.0002384.g005
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PLoS ONE | www.plosone.org 7 June 2008 | Volume 3 | Issue 6 | e2384Figure 6. Lymphocytes traffic to peripheral lymphoid tissues after adoptive transfer. A Diagram displaying the transfer protocol. B Donor
bulk PBMC were transferred from MCM7 into MCM6. MCM6 was euthanized 24 hours post transfer and its tissues were processed. Cells selectively
trafficked to different peripheral lymphoid organs post-transfer. C Immunohistochemical staining of a lymph node section showing PKH67+ cells
(green), CD20 antibody staining (red) and CD8 antibody staining (blue) collected with a confocal microscope at 200X.
doi:10.1371/journal.pone.0002384.g006
Adoptive Transfers in Macaques
PLoS ONE | www.plosone.org 8 June 2008 | Volume 3 | Issue 6 | e2384different vaccine modalities, accelerating the advancement of
promising candidates through the vaccine pipeline. In these ways,
the demonstration of successful allogeneic adoptive transfer in
MCM may pave the way for the identification of the necessary
immune responses that protect against SIV in vivo.
Materials and Methods
Animals and SIVmac239 Challenge
Wepurchased bloodsamplesfrom feral MCM forgeneticanalysis
(Charles River BRF, Houston, TS). Blood from 117 feral MCM was
obtained for genetic analysis. Animal pairs were identified based on
microsatellite analysis as described previously [35].
MCM1-MCM7 were challenged intrarectally with single doses
of 50,000 TCID50 of molecularly cloned SIVmac239 Nef open
virus [47]. Animal studies were approved by University of
Wisconsin Institutional Animal Care and Use Committee
(IACUC). SIV-infected animals were cared for according to the
regulations and guidelines of the IACUC by members of the
Wisconsin National Primate Research Center (WNPRC).
Whole Genome Amplification and Microsatellite Analysis
At 7 days post-transfer PKH67+ cells from MCM3 were sorted
on a MoFlow cell sorter (DakoCytomation, Fort Collins, CO).
DNA from approximately 600 cells was subjected to whole
genome amplification (Qiagen RepliG Kit). Microsatellite analysis
was performed with the whole genome amplified product from
PKH67+ cells as well as genomic DNA prepared from donor
MCM1 and recipient MCM3 PBMC prior to transfer essentially
as described previously [35]. The following PCR primers were
used in this analysis: D3S3045-F, 59-ACCAAATGAGA-
CAGTGGCAT and D3S3045-R, 59-ATGAGGACGGTTGA-
CATCTG. D3S3045-F was fluorescently labeled with HEX (6-
carboxy-29,4 ,4 9,5 9,7 ,7 9-hexachlorofluorescein) to facilitate
detection of PCR products with an ABI 3730xl DNA Analyzer
(Applied Biosystems, Foster City, CA). The D3S3045 microsatel-
lite marker was selected because it was found to be informative for
the MCM1 donor cells and the MCM3 recipient animal.
Mixed Lymphocyte Reaction
Blood was drawn into EDTA tubes. PBMC was isolated from
EDTA treated blood by Ficoll-Paque PLUS (GE Health Sciences,
Piscataway, NJ) density centrifugation. Stimulator cells were
irradiated and resuspended at 2610
6 cells/ml. One ml of the
stimulator cell suspension was added to each well of a 24 well
plate. 2610
6 PKH67 (Sigma-Aldrich, Saint Louis, MO) responder
cells were added to the wells in a 1:1 ratio with the stimulator cells
and plates were incubated for 6 days. Cells were harvested on day
6 and phenotyped and run on a BD FACSCalibur (Becton
Dickinson Biosciences, San Diego, CA).
Cell Transfers
Blood was drawn from the donor animal and PBMC was
isolated from EDTA treated blood by Ficoll-Paque PLUS (GE
Health Sciences, Piscataway, NJ) density centrifugation. Spleen
and mesenteric lymph node were processed by dicing and forcing
through a 100 uM filter (BD Biosciences). We proceeded to
process cells as we did for the PBMC. Cells were then isolated by
staining with an anti-CD8ß+ PE antibody, clone 2ST8.5H7
(Beckman Coulter, Fullerton, CA) then subsequently labelled with
anti-PE microbeads, and subjected to magnetic separation with LS
Columns (Miltenyi Biotec, Auburn, CA). Purified cells were
labelled with PKH67 (Sigma-Aldrich) according to the manufac-
turer’s protocol. Cells were resuspended in 3 to 5 mls of PBS
containing 15u/ml sterile heparin (USB Corporation, Cleveland,
OH). Cells were transfused into the saphenous vein by the animal
care staff at the WNPRC. For the autologous transfer and first
allogeneic transfer, we transferred 17 million cells and 10 million
cells, respectively, using only PBMC isolated from the blood. In
the second allogeneic transfer we transfused 60 million bulk
PBMC. For the final allogenic transfer, cells from spleen, lymph
node, and PBMC were combined into a cell suspension. This
combination of cells was purified and labeled, and 220 million cells
were transferred into each animal.
Staining
Cells were phenotyped using the following antibodies and run
on the BD FACSCalibur (BD Biosciences): CD3-APC clone SP34-
2 (BD Biosciences), CD8ß-PE clone 2ST8.5H7 (Beckman
Coulter); CD3-APC (BD Biosciences), CD8a-PerCP clone SK1
(BD Biosciences); CD3-APC (BD Biosciences), CD4-PerCP clone
SK3 (BD Biosciences).
Fresh tissue immunohistochemistry
Fresh lymph nodes were placed into cold RPMI containing
100ug/ml heparin and shipped on ice blocks overnight to Dr.
Pamela Skinner’s laboratory for fresh tissue sectioning and
immunohistochemistry. Immediately upon arrival, the tissues were
cut into 200 micron thick sections using a vibratome and placed in
24-well tissue culture plates with cold phosphate buffered saline
containing 100mg/ml heparin (PBS-H). Free floating sections
were incubated overnight on a rocking platform at 4uC with
purified mouse-anti-human CD8 antibodies (Dako) diluted 1:200
in a blocking solution of PBS-H containing 2% normal goat
serum. The following day, sections were washed in PBS-H, fixed
with 4% paraformaldehyde for 2 hours at room temperature,
rinsed briefly, boiled in 0.1M Urea, and permeabolized and
blocked in blocking solution containing 0.3% Triton X-100. The
sections were then incubated at 4uC overnight with purified
rabbit-anti-human CD20 antibodies (Lab Vision) diluted 1:100 in
blocking solution containing 0.3% Triton X-100. The sections
were washed with PBS-H, and incubated at 4uC overnight with
Cy3-conjugated goat anti-rabbit (1:5000) and Cy5-conjugated
goat anti-mouse antibodies (1:2000) (Jackson ImmunoResearch) in
blocking solution containing 0.3% Triton X-100. Finally, sections
were washed in PBS-H and post-fixed with 4% paraformaldehyde,
rinsed and mounted with glycerol gelatin (Sigma) containing 4
mg/ml n-proply gallate and examined and imaged using an
Olympus FV 500 or 1000 confocal microscope.
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